CalciMedica, Inc. (CALC), Wednesday announced the discontinuation of its Phase 2 KOURAGE clinical trial following a recommendation from the trial's Independent Data Monitoring Committee, which identified a safety concern prompting a reevaluation of the study design, especially the patient enrollment criteria.
The study evaluated Auxora in patients with Stage 2 or Stage 3 acute kidney injury with associated acute hypoxemic respiratory failure.
CEO Rachel Leheny commented, "To date, no treatment-related safety concern has been observed across more than 350 critically ill patients treated with Auxora in completed clinical trials, including the Phase 2b CARPO trial in acute pancreatitis (AP) and the Phase 2 CARDEA trial in severe COVID-19 pneumonia."
Following the recommendation, the company has discontinued the trial and plans to perform a comprehensive review, assessing the impact of baseline characteristics, disease severity, concomitant therapies, and other factors on patient outcomes.
CalciMedica aims to finalize the design of a pivotal trial in acute pancreatitis in the first half of 2026.
Currently, CalciMedica's stock is plummeting 83.17 percent or $4.24, to $0.88 on the Nasdaq.
For comments and feedback contact: editorial@rttnews.com
Business News
June 12, 2026 17:14 ET Major central bank action was the focus this week in economic news. The European Central Bank became the first major central bank to move in response to the rising inflationary pressures in the backdrop of the conflict in the Middle East. In North America, the U.S. inflation and trade data as well as Canada’s central bank decision gained attention. The Chinese trade data was the main news in Asia.